Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting

Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy in 2022, while elranatamab, linvoseltamab, F182112, talquetamab, and cevostamab are curren...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Juanjuan, Ren, Quan, Liu, Xinyuan, Guo, Xiangqian, Song, Yongping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401827/
https://www.ncbi.nlm.nih.gov/pubmed/37537597
http://dx.doi.org/10.1186/s13045-023-01489-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401827/
https://www.ncbi.nlm.nih.gov/pubmed/37537597
http://dx.doi.org/10.1186/s13045-023-01489-3

Ejemplares similares